Depression — one of the most prevalent mental health conditions globally — generates a sustained demand for therapeutic options beyond the conventional pharmacological repertoire. A growing body of research, including clinical trials and observational studies, examines whether substances such as ayahuasca, psilocybin and ibogaine, used in adequate contexts, may have a role in addressing depressive symptoms, treatment-resistant cases and the existential dimensions of the experience. ICEERS gathers here content on depression and its intersection with traditional medicines.
